[1] Lin C H, Chen M L, Tai Y C, et al. Reaffirmation of GAK, but not HLA-DRA, as a Parkinson's disease susceptibility gene in a Taiwanese population[J]. Am J Med Genet B Neuropsychiatr Genet, 2013,162(8): 841-846. [2] Mizuta I, Takafuji K, Ando Y, et al. YY1 binds to alpha-synuclein 3'-flanking region SNP and stimulates antisense noncoding RNA expression[J]. J Hum Genet, 2013,58(11): 711-719. [3] Brockmann K, Schulte C, Hauser A K, et al. SNCA: major genetic modifier of age at onset of Parkinson's disease[J]. Mov Disord, 2013, 28(9):1217-1221. [4] Chang C, Lang H, Geng N, et al. Exosomes of BV-2 cells induced by alpha-synuclein: important mediator of neurodegeneration in PD[J]. Neurosci Lett, 2013, 548: 190-195. [5] Shaltiel-Karyo R, Frenkel-Pinter M, Rockenstein E, et al. A blood-brain barrier (BBB) disrupter is also a potent alpha-synuclein (alpha-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD)[J]. J Biol Chem, 2013, 288(24): 17579-17588. [6] Helferich A M, Ruf W P, Grozdanov V, et al. alpha-synuclein interacts with SOD1 and promotes its oligomerization[J]. Mol Neurodegener, 2015, 10: 66. [7] Szunyogh S, Olah J, Szenasi T,et al. Targeting the interface of the pathological complex of alpha-synuclein and TPPP/p25[J]. Biochim Biophys Acta, 2015, 1852(12): 2653-2661. [8] Follmer C, Coelho-Cerqueira E, Yatabe-Franco D Y, et al. Oligomerization and membrane-binding properties of covalent adducts formed by the interaction of alpha-synuclein with the toxic dopamine metabolite 3,4-Dihydroxyphenylacetal-dehyde (DOPAL)[J]. J Biol Chem, 2015, 290(46): 27660-27679. [9] Zhang Z, Hou L, Li X, et al. Neruoprotection of inositol hexaphosphate and changes of mitochondrion mediated apoptotic pathway and α-synuclein aggregation in 6-OHDA induced parkinson's disease cell model[J].Brain Res,2016, 1633: 87-95. [10] Ascenzi P, Gustincich S, Marino M. Mammalian nerve globins in search of functions[J]. IUBMB Life,2014, 66(4): 268-276. [11] Biagioli M, Pinto M, Cesselli D, et al. Unexpected expression of alpha- and beta-globin in mesencephalic dopaminergic neurons and glial cells[J]. Proc Natl Acad Sci U S A, 2009, 106(36): 15454-15459. [12] Richter F, Meurers B H, Zhu C, et al. Neurons express hemoglobin alpha- and beta-chains in rat and human brains[J]. J Comp Neurol, 2009, 515(5): 538-547. [13] Wilson M T, Reeder B J. Oxygen-binding haem proteins[J]. Exp Physiol, 2008, 93(1): 128-132. [14] Gorgun F M, Zhuo M, Singh S, et al. Neuroglobin mitigates mitochondrial impairments induced by acute inhalation of combustion smoke in the mouse brain[J]. Inhal Toxicol, 2014, 26(6): 361-369. [15] Kawada N, Kristensen D B, Asahina K, et al. Characterization of a stellate cell activation-associated protein (STAP) with peroxidase activity found in rat hepatic stellate cells[J]. J Biol Chem, 2001, 276(27): 25318-25323. [16] Kawada N. Current situation and future prospect of cytoglobin research[J]. Nihon Rinsho,2013, 71(5): 927-935. [17] Burmester T, Ebner B, Weich B, et al. Cytoglobin: a novel globin type ubiquitously expressed in vertebrate tissues[J]. Mol Biol Evol, 2002, 19(4): 416-421. [18] 李维德,孙青,李松,等. 脑红蛋白在蛛网膜下腔出血大鼠脑组织中的表达[J]. 中国脑血管病杂志, 2013,10(8):416-420. [19] Shephard F, Greville-Heygate O, Marsh O, et al. A mitochondrial location for haemoglobins--dynamic distribution in ageing and Parkinson's disease[J]. Mitochondrion,2014(1), 14: 64-72. [20] Cheng F, Li X, Li Y, et al. alpha-Synuclein promotes clathrin-mediated NMDA receptor endocytosis and attenuates NMDA-induced dopaminergic cell death[J]. J Neurochem, 2011, 119(4): 815-825. [21] Schloesser A, Esatbeyoglu T, Piegholdt S, et al. Dietary tocotrienol/gamma-cyclodextrin complex Increases mitochondrial membrane potential and ATP concentrations in the brains of aged mice[J]. Oxid Med Cell Longev,2015, 2015: 789710. |